A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Feb 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary)
Indications Solid tumours
Focus Pharmacokinetics
Sponsors AstraZeneca

Most Recent Events

01 Feb 2019 Planned End Date changed from 28 Dec 2018 to 31 Dec 2019.
19 Jan 2018 Planned End Date changed from 29 Dec 2017 to 28 Dec 2018.
12 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight